An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma

被引:33
作者
Michon, JM
Hartmann, O
Bouffet, E
Meresse, V
Coze, C
Rubie, H
Bordigoni, P
Cattiaux, E
Ward, N
Bernard, JL
Lemerle, J
Zucker, JM
Philip, T
机构
[1] Inst Curie, Dept Paediat Oncol, F-75231 Paris 5, France
[2] Inst Gustave Roussy, Villejuif, France
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] CHU La Timone, Marseille, France
[5] CHU Purpan, Toulouse, France
[6] CHU Brabois, Nancy, France
关键词
neuroblastoma; filgrastim; neutropenia; infection; chemotherapy; dose intensity; children;
D O I
10.1016/S0959-8049(98)00061-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Administration of combination chemotherapy to children with metastatic neuroblastoma induces profound myelosuppression resulting in chemotherapy treatment delays and febrile neutropenic episodes. The objective of this randomised multicentre study was to assess the incidence, duration and severity of neutropenia when filgrastim is added to induction chemotherapy administered to patients with metastatic neuroblastoma. In this study, 59 patients with metastatic neuroblastoma were randomised to receive chemotherapy (control group, n = 28) or chemotherapy plus filgrastim (filgrastim group, n = 31). Chemotherapy consisted of four cycles of cyclophosphamide, vincristine and doxorubicin (CADO) alternating at 21-day intervals with cisplatin and etoposide (CDDP-VP16). Filgrastim was administered subcutaneously at a dose of 5 mu g/kg/day from day 7 for up to 14 days. The incidence of neutropenia (absolute neutrophil count [ANC] < 0.5 x 10(9)/l) in the filgrastim group was not reduced after the first CADO course. However, significant reductions were observed after courses 2, 3 and 4. The duration of neutropenia and of intravenous antibiotic use were significantly reduced in the filgrastim group over the whole study period (9 days versus 26 days, P < 0.001; 12 days versus 20 days, P = 0.04, respectively). However, the duration of hospitalisation and the incidence of febrile neutropenia were not significantly reduced. Compliance to treatment was good and the ability to administer chemotherapy without treatment delays was significantly better in the filgrastim group (P < 0.05). Event-free survival was greater in the filgrastim than in the control group (2.4 years versus 1.3 years; P = 0.072). Filgrastim is a beneficial adjunct to combination induction chemotherapy used in the treatment of metastatic neuroblastoma. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1063 / 1069
页数:7
相关论文
共 20 条
[1]   SEQUENTIAL CISPLATIN-VM-26 AND VINCRISTINE CYCLOPHOSPHAMIDE DOXORUBICIN IN METASTATIC NEUROBLASTOMA - AN EFFECTIVE ALTERNATING NON-CROSS-RESISTANT REGIMEN [J].
BERNARD, JL ;
PHILIP, T ;
ZUCKER, JM ;
FRAPPAZ, D ;
ROBERT, A ;
MARGUERITTE, G ;
BOILLETOT, A ;
PHILIPPE, N ;
LUTZ, P ;
ROCHE, H ;
PINKERTON, R .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (12) :1952-1959
[2]   EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR ON NEUTROPENIA IN PATIENTS WITH CONGENITAL AGRANULOCYTOSIS [J].
BONILLA, MA ;
GILLIO, AP ;
RUGGEIRO, M ;
KERNAN, NA ;
BROCHSTEIN, JA ;
ABBOUD, M ;
FUMAGALLI, L ;
VINCENT, M ;
GABRILOVE, JL ;
WELTE, K ;
SOUZA, LM ;
OREILLY, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (24) :1574-1580
[3]   INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].
BRODEUR, GM ;
SEEGER, RC ;
BARRETT, A ;
BERTHOLD, F ;
CASTLEBERRY, RP ;
DANGIO, G ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
FREEMAN, AI ;
HAASE, G ;
HARTMANN, O ;
HAYES, FA ;
HELSON, L ;
KEMSHEAD, J ;
LAMPERT, F ;
NINANE, J ;
OHKAWA, H ;
PHILIP, T ;
PINKERTON, CR ;
PRITCHARD, J ;
SAWADA, T ;
SIEGEL, S ;
SMITH, EI ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881
[4]   PHASE-I/II STUDY OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR IN PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY FOR SMALL CELL LUNG-CANCER [J].
BRONCHUD, MH ;
SCARFFE, JH ;
THATCHER, N ;
CROWTHER, D ;
SOUZA, LM ;
ALTON, NK ;
TESTA, NG ;
DEXTER, TM .
BRITISH JOURNAL OF CANCER, 1987, 56 (06) :809-813
[5]   CHEMOTHERAPY DOSE INTENSITY CORRELATES STRONGLY WITH RESPONSE, MEDIAN SURVIVAL, AND MEDIAN PROGRESSION-FREE SURVIVAL IN METASTATIC NEUROBLASTOMA [J].
CHEUNG, NKV ;
HELLER, G .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (06) :1050-1058
[6]   REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
CRAWFORD, J ;
OZER, H ;
STOLLER, R ;
JOHNSON, D ;
LYMAN, G ;
TABBARA, I ;
KRIS, M ;
GROUS, J ;
PICOZZI, V ;
RAUSCH, G ;
SMITH, R ;
GRADISHAR, W ;
YAHANDA, A ;
VINCENT, M ;
STEWART, M ;
GLASPY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :164-170
[7]  
FURMAN WL, 1992, PEDIATRICS, V90, P716
[8]   EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR ON NEUTROPENIA AND ASSOCIATED MORBIDITY DUE TO CHEMOTHERAPY FOR TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM [J].
GABRILOVE, JL ;
JAKUBOWSKI, A ;
SCHER, H ;
STERNBERG, C ;
WONG, G ;
GROUS, J ;
YAGODA, A ;
FAIN, K ;
MOORE, MAS ;
CLARKSON, B ;
OETTGEN, HF ;
ALTON, K ;
WELTE, K ;
SOUZA, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (22) :1414-1422
[9]   RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR REDUCES HEMATOLOGIC TOXICITY AND WIDENS CLINICAL APPLICABILITY OF HIGH-DOSE CYCLOPHOSPHAMIDE TREATMENT IN BREAST-CANCER AND NON-HODGKINS-LYMPHOMA [J].
GIANNI, AM ;
BREGNI, M ;
SIENA, S ;
ORAZI, A ;
STERN, AC ;
GANDOLA, L ;
BONADONNA, G .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) :768-778
[10]  
MICHON J, 1989, AUTOLOGOUS TRANSPLAN, P529